Publications by authors named "G A Held"
Selective catalytic oxidation (SCO) of NH to N is one of the most effective methods used to eliminate NH emissions. However, achieving high conversion over a wide operating temperature range while avoiding over-oxidation to NO remains a significant challenge. Here, we report a bi-metallic surficial catalyst (PtCuO/AlO) with improved Pt atom efficiency that overcomes the limitations of current catalysts.
View Article and Find Full Text PDFOperando Characterization of Electrochemistry at the Rutile TiO(110)/0.1 M HCl Interface Using Ambient Pressure XPS.
J Phys Chem C Nanomater Interfaces
December 2024
Ambient pressure X-ray photoelectron spectroscopy (AP-XPS) was employed to investigate the effect of applied potential on the interface of TiO(110) with 0.1 M HCl. The study, which involved operando electrochemical characterization, enabled real-time monitoring and analysis of electrochemical processes.
View Article and Find Full Text PDFArticle Synopsis
- CMV reactivation is a significant health issue for patients who have undergone stem cell or organ transplants, leading to increased risks of illness and death.
- Three CMV-specific Fab-antibodies (A6, C1, C7) have been developed to bind to particular MHC molecules, showing effectiveness in targeting and destroying CMV-infected cells, especially when used in combination with natural killer (NK) cells.
- The TCR-like antibodies also demonstrated the ability to activate neutrophils to kill target cells, offering a promising treatment option for patients experiencing or at risk of CMV reactivation, with a broader potential patient application than previous methods.
Purpose: To determine the optimal daunorubicin dose and number of 7 + 3 induction cycles in newly diagnosed AML, this randomized controlled trial compared a once daily dose of 60 mg/m with 90 mg/m daunorubicin in the first 7 + 3 induction and one versus two cycles of 7 + 3 induction.
Patients And Methods: Patients age 18-65 years with newly diagnosed AML were randomly assigned to 60 versus 90 mg/m daunorubicin once daily plus cytarabine. Patients with marrow blasts below 5% on day 15 after first induction were randomly assigned to receive a second induction cycle or no second induction cycle.
Article Synopsis
- The article in question has a specific DOI for referencing purposes, which allows readers to access the original content easily.
- The DOI provided indicates that there was a need for correction related to the information or findings presented in the article.
- This correction is necessary to ensure the accuracy and reliability of the research for scholars and readers accessing the publication.